secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001193125-25-015646
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences appoints Adele M. Gulfo to board; Nina Kjellson resigns
------------------------------------------------------------------------

- Nina Kjellson resigned from board and Compensation Committee effective Jan 29, 2025, not due to disagreement.
- Adele M. Gulfo appointed as Class I director and to Compensation Committee effective same date.
- Gulfo, 62, former CEO Sumitomo Pharma America Biopharma Commercial Unit (Jul 2023-Oct 2024) and prior roles at Sumitovant, Roivant, Mylan, Pfizer, AstraZeneca.
- Gulfo received options for 37,200 shares vesting over 36 months and cash compensation per non-employee director program.
- Board determined Gulfo independent under Nasdaq rules; no material transactions with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/0001193125-25-015646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525015646/d922700d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-015646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer